symptoms

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by two forum topics about silent inflammation from August 2019. Have an experience you want…

Tysabri (natalizumab), an effective T-cell targeting treatment for multiple sclerosis (MS), seems to also promote the activation of pro-inflammatory immune B-cells in people with this disease, a study found. The study, “Natalizumab promotes activation and pro-inflammatory differentiation of peripheral B cells in multiple sclerosis patients,” was published in the…

After having multiple sclerosis for six years, I’ve decided there are five things “healthy” people might not understand about the disease, and it really drives me crazy.  So, I’ve compiled some common misconceptions and advice to help spread awareness among those who aren’t familiar…

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topic “Are urinary tract infections a reoccurring problem for you ?” from Feb.

Can your mind control your illness? You might think, “No, of course not, the illness will do what it’ll do. I have no control over that.” What if I told you that you might have more control over it than you think?  When I…

I was bruised, broken, and in pain. I had been struggling with Rebif (interferon beta-1a) side effects for over a year, ever since my diagnosis. It was the first multiple sclerosis medication doctors put me on, and it did not work…

Vumerity (diroximel fumarate) carries fewer and less severe gastrointestinal side effects compared to Tecfidera (dimethyl fumarate), new data from a Phase 3 trial directly comparing the GI tolerability of these two relapsing-remitting multiple sclerosis (RRMS) treatments show. These results were presented at the 27th Annual Meeting of the European Charcot Foundation,…

A DNA analysis to identify changes in the gut microbiome in people newly diagnosed with multiple sclerosis — who have yet to begin using disease-modifying therapies — showed that all, regardless of ethnic background, have an abundance of the bacteria group Clostridia compared to people…

Editor’s note: “Need to Know” is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topic “Are you still driving? Should you be?” from Dec. 27, 2018. At…

It is 2 a.m. and I am awake. I sit on the couch with my head in my hands. The leg pain that broke my slumber is now extreme. I have taken my medications, used my topical, and applied heat. All to no avail. Exhaustion meets pain as my eyes…

Pregnancy does not lead to long-term changes in the disease course of multiple sclerosis (MS), new research suggests. This work, which emphasizes the importance of careful data analysis, supports studies disputing previous beliefs that pregnancy worsened or lessened the long-term disease course of MS. The findings were presented by Mar Tintore,…

A large retrospective study suggests that a magnetic resonance imaging (MRI) marker — called “brain atrophied T2 lesion volume” — could help predict the timing of multiple sclerosis (MS) progression. According to the study, this marker was the only MRI parameter capable of predicting disease progression, compared with other…

Fear grips me. Marijuana relaxes, eases pain, and helps my body work better. It also stirs paranoia, but only when you let it. In bed, a fretful waking dream. This is a problem when you actually have something to be paranoid about! I don’t remember all my last times…

The Committee for Medicinal Products for Human Use (CHMP) issued an opinion supporting Mayzent (siponimod) as an oral treatment specifically for adults with active secondary progressive multiple sclerosis (SPMS) in the European Union. Opinions released by CHMP, an arm of the European Medicines Agency (EMA), carry weight and are…

With the help of 7 Tesla magnetic resonance imaging (MRI), investigators discovered that leptomeningeal enhancement — a radiographic finding indicative of brain inflammation — is more common than previously thought in people with relapsing-remitting multiple sclerosis (RRMS), and is tied to lesions in specific regions of the brain.